Sp654
DEBATE: STEP DOWN THERAPY STARTING WITH BIOLOGICS
Date
May 19, 2024
Explore related products in the following collection:
Presenter
University of North Carolina School of Medicine
Tracks
Related Products
EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDY
BACKGROUND: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders…
HISTOLOGIC RESPONSE OR ENDOSCOPIC NORMALIZATION AFTER INTITIAL TREATMENT FOR EOSINOPHILIC ESOPHAGITIS IN CHILDREN LEADS TO LESS FIBROSTENOSIS OVER LONG-TERM FOLLOW-UP
BACKGROUND: Untreated eosinophilic esophagitis (EoE) can result in development of fibrostenosis over time, but there are few data on whether successful treatment in childhood decreases this risk as children with EoE transition to adulthood…
FLUTICASONE PROPIONATE ORAL DISINTEGRATING TABLET, APT-1011, LEADS TO A GREATER COMPLETE SYMPTOMATIC RESPONSE RATE COMPARED TO PLACEBO IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
The goals of treatment of eosinophilic esophagitis (EoE) are to improve clinical symptoms and histologic features, as well as prevent progression to fibrostenotic complications. Few data currently exist that evaluate the effectiveness of therapies as measured by complete resolution of symptoms…
WEIGHT GAIN IS ASSOCIATED WITH DECREASED TREATMENT RESPONSE TO DIET THERAPY IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS
BACKGROUND: Dietary therapy is an effective treatment for eosinophilic esophagitis (EoE), however, the influence of body mass index (BMI) on treatment response is unclear…
